DSM, Patheon hook up for pharma-services glory in $2.6B deal

Netherlands-based Royal DSM has for several years been doing smaller deals to beef up its pharma contract development and manufacturing business. So has Canada-based Patheon ($PTI). Now, the two operations will join in a deal valued at $2.6 billion that they say will make them a major force in the pharma services business. Report

Suggested Articles

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."

With suitor Takeda circling Shire, the Dublin-based target has pulled off a deal of its own.